Study of TPD3310 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your cancer must be advanced and not responding to or tolerable of standard treatments.
- You need to have a tumor that can be measured on scans and have a marker called c-MET (test will be done).
- You should be in reasonably good health, able to care for yourself (ECOG score 0 or 1).
- Your blood counts, liver, and kidney functions must meet certain levels (tests will be done).
- You cannot have certain other health issues like active infections, heart problems, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new drug, PTT-936, alone or with other treatments, for people with solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This trial is testing whether a new drug called CT7439 can help people with advanced solid tumors that have not responded to other treatments. It is a phase 1/2 study that also checks the drug's safety and how well it works.
This trial tests a new oral drug called EP102 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug is safe and works by targeting a protein called METTL3.
Hear when a new Advanced Malignant Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.